Replies to post #5042 on Enanta Pharmaceuticals Inc (ENTA)

[DC15]

"It wasn't a loan", some might say. Yet everyone understands the phrase, "pay them back."

[dewophile]

the more relevant factor is the NPV of the remaining 45.5% royalty. If you not only reverse the decline but also get an additional modest boost to HCV sales, which so far seems likely albeit early days, then the residual value of the royalty goes up quite a bit

[dewophile]

It's worth noting that between 1B and 1.5B in Mavyret sales the royalty goes up to 6%, so any increment is looking like it will fall in this royalty tier (12% vs 10% on the glecaprevir component when sales attributed to the PI are in the 500M and 750M range)
If somehow Mavyret sales get north of 1.5 B annually - a longer shot of course - the you are in the 14% royalty bracket (7% for the PI component)